Figure 4. Box-and-whisker plots showing the IMS signal intensity of peak-2 in adenocarcinoma patients positive and negative for EGFR.

Fourteen patients with EGFR mutation displayed a significantly higher n-Dodecane peak with a sensitivity of 85.7% and a specificity of 78.6% (p<0.01) than in 14 adenocarcinoma patients without the EGFR mutation.